{"id":4677,"date":"2025-03-31T18:12:16","date_gmt":"2025-03-31T18:12:16","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/sertraline-txt\/"},"modified":"2025-03-31T18:12:16","modified_gmt":"2025-03-31T18:12:16","slug":"sertraline-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/sertraline-txt\/","title":{"rendered":"sertraline.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nSSRI:Antidepressant Post-traumatic stress disorder Obsessive compulsive disorder

DOSE IN NORMAL RENAL FUNCTION <\/H3>25\u2013200 mg daily depending on indication

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :342.7 (as hydrochloride)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :>98<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 0<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :25<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :26\/Probably unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Analgesics: increased risk of bleeding with aspirin and NSAIDs; risk of CNS toxicity increased with tramadol\n
  • Anticoagulants: effect of coumarins possibly enhanced\n
  • Antidepressants: increased risk of toxic CNS effects of MAOIs and moclobemide; sertraline and MAOIs should not be prescribed within a 2 week period of each other; avoid concomitant use with St John\u2019s wort; possibly enhanced serotonergic effects with duloxetine; can increase tricyclics antidepressant concentration; increased agitation and nausea with tryptophan\n
  • Anti-epileptics: antagonism (lowered convulsive threshold)\n
  • Antimalarials: avoid concomitant use with artemether\/lumefantrine\n
  • Antipsychotics: concentration of clozapine and pimozide increased \u2013 avoid concomitant use with pimozide\n
  • Antivirals: concentration reduced by efavirenz and darunavir; possibly increased concentration with ritonavir\n
  • Ciclosporin: may increase serotonin syndrome\n
  • Dopaminergics: increased risk of hypertension and CNS excitation with selegiline \u2013 avoid concomitant use; increased risk of CNS toxicity with rasagiline \u2013 avoid concomitant use\n
  • Dopaminergics: hypertension and CNS excitation5HT 1 agonist: increased risk of CNS toxicity with sumatriptan \u2013 avoid concomitant use; possibly increased risk of serotonergic effects with frovatriptanLinezolid: use with caution\n
  • Lithium: increased risk of CNS effects; lithium toxicity reported\n
  • Sibutramine: increased risk of CNS toxicity \u2013 avoid concomitant use

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Sertraline is extensively metabolised by the liver. It can be used in renal failure at normal doses with caution.
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE SSRI:Antidepressant Post-traumatic stress disorder Obsessive compulsive disorder DOSE<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4677","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4677"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4677\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}